Ann: Medibio Signs Agreement with PwC Australia for ilumen, page-219

you will find a range of reasons including mgt split, high costs, being run like a far greater capitalised company.

If if you dig deep enough youlll also find significant debate on the outcomes of a trial being done with US Mayo clinic for FDA approval process in Sept 18 which was the start of the decline which landed on 70 % diagnostic specificity and much debate on whether this was sufficient for FDA approval as a stand alone diagnostic tool.

Considering
- the algorithms had to stand on their own versus a medical practitioner,
- as opposed to complimenting the practitioners skills to provide a combined better outcome
- a 20-40% improvement in current diagnostic standard seemed a great result to me.

I look at MEB history a little bit like RAPs famous trial misfire and Phoenix like rise from the ashes. University of humanitas certainly seem to think so, as did the assessment teams who have already provided CE and TGA approval which let’s remind ourselves is only as far as RAP has got so far also

https://www.asx.com.au/asxpdf/20190417/pdf/444cs7hmx1td9g.pdf